Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.25. Hemispherx BioPharma shares last traded at $0.22, with a volume of 864,053 shares traded.
Hemispherx BioPharma Trading Down 11.8 %
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Read More
- Five stocks we like better than Hemispherx BioPharma
- Why Invest in 5G? How to Invest in 5G Stocks
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Top-Performing Non-Leveraged ETFs This Year
- Industrial Products Stocks Investing
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
